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Abstract
Background Implantable cardioverter-deﬁbrillators (ICDs)
reduce mortality in both primary and secondary prevention,
but are associated with substantial short- and long-term
morbidity. A totally subcutaneous ICD (S-ICD) system has
been developed. We report the initial clinical experience of
the ﬁrst 31 patients implanted at our hospital.
Methods All patients had an ICD indication according to
the ACC/AHA/ESC guidelines. The ﬁrst 11 patients were
partofthereportedCEtrial.Theimplantationwasperformed
without ﬂuoroscopy. The device was implanted subcutane-
ously in the anterior axillary line, with a parasternal lead
tunneled from the xiphoid to the manubrial–sternal junction.
Ventricular ﬁbrillation (VF) was induced to assess detection
accuracy and deﬁbrillation efﬁcacy using 65 J shocks.
Results Post-implant, 52 sustained episodes of VF were
induced. Sensitivity was 100% and induced conversion
efﬁcacy was 100% (with standard polarity in 29 patients).
Mean time to therapy was 13.9 ± 2.5 s (range 11–21.6 s).
Late procedure-related complications were observed in 2 of
the ﬁrst 11 implantations (lead migration). During follow-
up, spontaneous ventricular arrhythmias occurred in four
patients, with accurate detection of all episodes. Inappro-
priate therapy was observed in ﬁve patients. Recurrences
were prevented with reprogramming.
Conclusions The S-ICD system can be implanted without
the use of ﬂuoroscopy by using anatomical landmarks only.
Episodes of VF were accurately detected using subcuta-
neous signals, and all induced and clinical episodes were
successfully converted. The S-ICD system is a viable
alternative to conventional ICD systems for selected
patients.
Keywords Deﬁbrillator  Sudden cardiac death 
Ventricular ﬁbrillation  Ventricular tachycardia 
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Introduction
Implantable cardioverter-deﬁbrillators (ICDs) have become
standard therapy to prevent sudden cardiac death, but have
recently been associated with serious short- and long-term
morbidity, such as lead failure, premature depletion,
endocarditis and inappropriate shocks. A totally subcuta-
neous ICD (S-ICD) system has been developed to address
some of these concerns [1]. We report the initial clinical
experience of the ﬁrst 31 patients who received this device
in our department.
Methods
Patient population
Files of all patients receiving a totally subcutaneous car-
dioverter-deﬁbrillator in our institution were reviewed for
this report. Patients were selected for an S-ICD if they had
an ICD indication according to the ACC/AHA/ESC 2006
guidelines for primary or secondary prevention. A total of
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tem. The patient’s mean age was 53 ± 4 years. Left ven-
tricular ejection fraction was 38 ± 15%, which was
relatively high due to the number of patients with pro-
phylactic implantations for channelopathy or genetic dis-
ease (32% had LVEF[50%). Coronary artery disease was
present in 18 patients and the indication was primary
prophylaxis in 21 patients. Coronary artery disease was
present in 18 patients (58%), dilated cardiomyopathy in 4
(13%), Brugada disease in 2, idiopathic ventricular ﬁbril-
lation in 3, idiopathic VT in 2 and non-compaction car-
diomyopathy and valvular disease were diagnosed each in
1 patient. Demographic data are given in Tables 1, 2.
ECG showed an infarction in 13 patients. The mean PR
interval was 165.2 ± 31.6 ms with one patient in atrial
ﬁbrillation at the time of implant. The mean QRS width was
105 ± 16.2 ms. No QT abnormalities were observed; three
patientshadanincompleteleftbundlebranchblock(LBBB),
three had a complete LBBB and one an intermittent RBBB.
In addition, we checked a 24 h recording to exclude
evident bradycardia or high degree block at the time of
implant. The mean heart rate during the 24 h Holter was
70 ± 8 beats/min. The minimal and maximal heart rates
were 48 ± 5 and 111 ± 17 beats/min, respectively; the
mean longest RR interval was 1,281 ± 149 ms. Two
patients previously had a transvenous ICD explantation,
one for hematoma and painful deep venous thrombosis, and
the other for a pace-sense lead break.
Most patients were admitted on the day of the procedure
and discharged on the following day. All gave informed
consent and were aware of the innovative aspects, limita-
tions and potential advantages and disadvantages of the
device.
Beta-blocking agents and antiarrhythmic drugs were
continued. Prior to implantation, oral anticoagulation was
discontinued until the INR was normalized. Patients with
frequent ventricular arrhythmias necessitating ICD therapy
and those with a pacing indication were not considered for
thisdevice.Theﬁrst11patientswereincludedinthestudyby
Bardyetal.[1]whichonlyreportedafollow-upof3 months.
The device and its programming
The subcutaneous ICD system (model SQ-RX 1010;
Cameron Health Inc., San Clemente, CA, USA), comprises
a pulse generator and a subcutaneous lead (model Q-Trak
3010; Cameron Health Inc.) with two sensing electrodes to
record the electrical activity of the heart. These electrodes
represent three vector projections of electrical conduction
occurring through the heart (A-to-CAN, B-to-CAN, and
A-to-B) (Fig. 1). The S-ICD system operates by analyzing
both the rate and morphological characteristics of the
detected rhythm. The device can be programmed as single
zone or dual zone. The device calculates heart rate based
on the average of the last four intervals. As soon as the
heart rate crosses the lowest programmed detection zone,
further analysis is performed to determine whether therapy
is required. Therapy consists of an 80 J shock, with
potential temporary transthoracic back-up pacing for 30 s.
Implantation procedure
General anesthesia was used for the ﬁrst two patients, and
for the rest local anesthesia was given in combination with
Table 1 Clinical characteristics of patients implanted with an S-ICD
Characteristics Value
Number 31
Age (years ± SD) 53 ± 16
Gender (male/female) 24/7
Height (cm ± SD) 175 ± 10
Weight (kg ± SD) 79 ± 17
BMI (kg/m
2 ± SD) 29 ± 16
LVEF (% ± SD) 38.8 ± 15
CAD (n) 18 (58%)
Primary prevention (n) 21 (67%)
ECG-PR[200 ms (n) 4 (13%)
QRS[120 ms (n) 4 (13%)
Holter
Mean HR (beats/min ± SD) 70 ± 8
Minimal HR (beats/min ± SD) 48 ± 5
Longest RR interval (ms ± SD) 1,281 ± 149
BMI body mass index, CAD coronary disease, HR heart rate, LVEF
left ventricular ejection fraction, SD standard deviation, S-ICD sub-
cutaneous deﬁbrillator, n number
Table 2 Patient characteristics
Pathology Patient
number
Percentage Average
LVEF
(%)
a
Coronary artery disease 18 58 30.6
Idiopathic VF (genetic
determination)
3 9.5 60
Idiopathic VT 2 6.5 65
Brugada syndrome 2 6.5 62
Idiopathic dilated
cardiomyopathy
4 13 25.5
Valvular disease 1 3.25 54
Non-compaction
cardiomyopathy
1 3.25 21
VT ventricular tachycardia, VF ventricular ﬁbrillation
a LVEF determined by echocardiography, nuclear scan or magnetic
resonance imaging
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123sedation, as done routinely for transvenous implantations.
Antibiotic prophylaxis was administered 1 h before the
procedure. The subcutaneous deﬁbrillator was implanted
without ﬂuoroscopy using anatomical landmarks only. The
pocket was created in the left axillary region at the level of
the sixth rib (Fig. 2). The parasternal deﬁbrillation lead
was placed left of the sternal midline using small incisions
at the xiphoid and at the sternal–manubrium junction. The
lead was pulled into position by tunneling from xiphoid to
the pocket, and subsequently from the xiphoid to the
sternal–manubrium junction. Fixation of the lead was
performed by a suture at the tip in all patients. After the
ﬁrst 15 patients, an additional suture sleeve was used at the
xiphoid position. For the deﬁbrillation efﬁcacy testing
(‘‘DFT’’), etomidate was given before VF was induced.
Two consecutive shocks of 65 J were required as per
protocol in the initial 13 patients. Polarity was reversed in
case of failure. After the initial series, only one effective
shock was performed. One day after the procedure, a chest
X-ray was taken to control ICD position.
Follow-up
After discharge, patients were seen in the device outpatient
clinic of our institute. After implantation, patients were
seen pre-discharge, 10 days and 2 months after implanta-
tion. Subsequently, patients underwent a regular ICD
interrogation at 6-monthly intervals or shorter if clinically
required. At each follow-up visit, arrhythmic events with
stored subcutaneous electrocardiograms (S-ECGs) were
retrieved from the device’s memory.
Results
Patients
A total number of 31 patients received an S-ICD between
December 2008, and October 2010.
Implantation
The implantations were usually done within 100 min
(average of 101 ± 33 min) including the DFT (with 3 min
between each attempt and up to three attempts before
external deﬁbrillation was used). They were performed by
a group of three electrophysiologists, including one in the
ﬁrst year of training, without using ﬂuoroscopy. No par-
ticular surgical problems were encountered. The proce-
dures under local anesthesia were relatively well tolerated;
only one patient was put under deep sedation for excessive
pain. The most time-consuming step was the making of a
lateral pocket. The DFT was performed after positioning
of the generator in the pocket without closing it com-
pletely. All patients could be converted from induced VF
to sinus rhythm, with the initial polarity (Fig. 3a), except
for two patients in whom reversed polarity was pro-
grammed. Non-sustained AF was induced by the shock in
three cases, but reverted spontaneously before the end of
the procedure and never triggered further activation of the
device. Post-shock bradycardia occurred in one patient,
which was resolved with pacing by the device (Fig. 3b).
All devices were programmed with maximal shocks
(80 J).
Fig. 1 S-ICD vector
conﬁguration shown on the
X-ray of a patient after
implantation. The drawing on
the right shows how the QRS
and the T-wave are assessed by
the device and the physician
before implantation, to ensure
that a correct vector will be
selected
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123Fig. 2 Lateral (at the left) and frontal (at the right) view of a patient
who received an S-ICD many years after coronary artery bypass
grafting (with a midsternal scar). The device and the lead are almost
invisible. The lateral incision was closed with seven discontinuous
stitches. The manubrial and xyphoid wounds are barely visible
Fig. 3 a Detection of induced VF and subsequent shock during deﬁbrillation threshold testing. b Transthoracic post-shock pacing after
conversion of induced ventricular ﬁbrillation
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123Follow-up
No record of unexplained syncope or death in our group
exists till now, with a median follow-up of 286 days (range
30–638) and a total number of 350 patient-months under
observation (till 1 October 2010).
Surgical problems
A late procedure-related complication was observed in two
of the ﬁrst 15 patients implanted, with dislocation of the
lead due to migration of the electrode. One of these patients
suffered from two inappropriate shocks due to myopoten-
tials. The other was detected with an X-ray during routine
control. Initial implanting recommendations did not utilize
an electrode suture sleeve at the xyphoid level, but this was
integrated into the implantation protocol thereafter. In both
cases, repositioning of the wires was done under local
anesthesia, with the addition of a dedicated suture sleeve
(Fig. 4) No further inappropriate therapy was noted in the
patient (239 ? days since implant). There was one case of
pocket infection with tissue necrosis, which led to explan-
tation of the entire system (without difﬁculty). This occur-
red in a 14-year-old boy in a cachectic state after treatment
with extracorporeal membrane oxygenation for severe heart
failure and an ongoing skin infection. The implantation was
carried out despite the infectious risk to allow revalidation
and because his life vest had become intolerable to him.
Inappropriate shocks
Five patients had inappropriate shocks. Two were clearly
due to myopotentials, one during vigorous sawing and the
above-mentioned lead displacement. These events occurred
prior to the software update, which speciﬁcally addressed
sensing during myopotentials. Since update, no inappro-
priate therapy has occurred (506? days). There was a case
of oversensing during heavy coughing and one case of
double counting after the appearance of a complete right
bundle branch block. The ﬁfth patient had an inappropriate
shock on a very fast sinus tachycardia, the sense vectors
were evaluated and a new vector was selected with an
updated template. No further inappropriate therapy has
been noted in this patient. These events are summarized in
Table 3.
Arrhythmias
All ventricular arrhythmias, detected in four patients, were
treated successfully (Fig. 5). This included 11 appropriate
Fig. 4 Initial position of lead (at the left), obvious lead displacement (in the middle) and after correction (at the right)
Table 3 Inappropriate shocks
Inappropriate
shocks (n)
Patient
number
Cause Solution Recurrence
Y/N
Interval from
implant
(days)
‘‘Arrhythmia’’
cycle length
detected (ms)
1 1 Myopotential detection (noise) Software upgrade N 237 160
2 1 Noise(myopotentials) from lead
dislodgment
Lead reposition N 461 260
15 1 T-wave oversensing (new RBBB) New template for EGM made N 59 200
1 1 Double counting Alternate vector selection N 421 300
1 1 T-wave oversensing Alternate vector selection N 625 300
RBBB right bundle branch block, EGM electrogram, Y yes, N no
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123shocks for ventricular ﬁbrillation in the patient with the
infection and correct detection of four episodes of non-
sustained arrhythmias in the VF zone. In one patient, six
shocks were delivered for ventricular tachycardia (VT)
[cycle lengths (CL) of 240, 250 and 260 ms], with correct
detection of seven episodes of non-sustained VT (CL 220,
240 and 260 ms). In this patient, the S-ICD was explanted
and replaced by a transvenous system to allow ATP and
also pacing for a later acquired symptomatic bradycardia.
There was detection of a non-sustained VT in two other
patients.
Discussion
Implantable cardiac deﬁbrillators are indicated in patients
with a high risk for sudden death. This is conﬁrmed after
the initial scientiﬁc studies by extensive meta-analysis and
reconﬁrmed in most international and national guidelines
[2–5]. Nevertheless, it became recently clear that some
disadvantages of ICDs can outweigh the advantages of a
prophylactic implantation [6]. Therefore it seems reason-
able to consider less invasive systems to offer the advan-
tage of internal deﬁbrillation to patients with a moderate
risk.
General advantages of SQ systems
The procedural advantages of subcutaneous systems are
evident [8]. The risk of vascular damage during implan-
tation is minimized. This implies that implantation is
possible in patients with congenital heart disease or after
extensive thrombosis or infection of the venous access. The
subcutaneous system was effective in all cases in our
experience. This was true for induced and spontaneous
arrhythmias. In our patient group, for two patients this ICD
was selected due to a complication from an endovascular
ICD (lead break and deep vein thrombosis). After a com-
plication implicating a transvenous device, patients are
reluctant to undergo a second implantation, and the stress
of possible complications related to explantation makes the
subcutaneous system even more attractive. Indeed, there is
no risk of endocarditis with infection and cardiac or venous
damage with an explantation. After implantation, patients
do not have to limit arm movements for 6 weeks, but only
for about a week to 10 days until the stitches are removed.
After implantation, there are no particular limitations in
movement of the arms, and this is indeed appreciated by
younger and more active patients. In our experience, this
has been of particular interest to younger patients with a
primary prevention indication in hereditary diseases such
as Brugada syndrome or genetic idiopathic ventricular
ﬁbrillation. A recent study involving 61 patients diagnosed
with Brugada syndrome suggests that programming a sin-
gle high-rate VF zone may be associated with reduced
inappropriate deﬁbrillator discharges [9].
Transvenous implantation can otherwise be associated
with right-sided venous thrombosis, endocarditis, surgical
complications, pocket bleeding and pneumothorax when
subclavian puncture is necessary [10]. Further, it became
clear in the recent years that lead related problems were
very often present and it is even said that after 10 years
only 80% of leads still function as anticipated [7, 11]. We
did not observe any of these disadvantages in our patients.
However, it must be noted that the longevity of subcuta-
neous leads is not yet well established. The only surgical
Fig. 5 Detection and
termination of spontaneous fast
ventricular tachycardia (coded
as T) with a shock, 18 s after
initiation of arrhythmia
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123problems we encountered were two lead migrations. This
occurred in the era before a suture sleeve was applied at the
xyphoid, which prevented migration in all the later
implanted patients. Further, we had one hematoma in a
very thin and generally ill patient in whom a life vest was
given because a transvenous device was judged to be an
impossible approach.
Speciﬁc advantages in comparison with conventional
devices
The subcutaneous device has incorporated some new
technology speciﬁcally for interpretation of the electro-
cardiogram and claims good arrhythmia discrimination in
the absence of transvenous leads. We observed inappro-
priate shocks in the beginning of this series. All events
were easily explained and by upgrading the template or the
software, spurious shocks could be further prevented.
Whether this incidence is higher or lower, in comparison
with conventional devices, has to be analyzed over a longer
period or in a randomized study. At this moment, we have
the impression that the incidents are reasonably further
avoided with optimal programming, better vector selection
and the introduction of the extra suture sleeve [12].
Speciﬁc disadvantages of subcutaneous systems
A potential disadvantage is that no bradycardia pacing and
anti-tachycardia pacing is possible. The absence of pacing
could more or less be considered an advantage for this
therapy, as it was shown that a certain amount of pacing is
associated with a decrease in left ventricular function. This
was initially shown for pacemaker patients and also for
patients requiring ICD therapy [13, 14]. No pacing also
implies no anti-tachycardia pacing. This could potentially
be of lesser concern when prophylactic implantations are
considered in particular where the target is indeed ven-
tricular ﬁbrillation. We only had one (secondary prophy-
laxis) patient in whom it was regretted that no ATP
facilities were present. He had also developed symptomatic
bradycardia.
The implantation procedure can in itself be quite pain-
ful, there are three scars instead of one, and the box is
heavier and larger and in a more sensitive part of the
thorax. Patients reported pain and the need for pain med-
ication, but it was mostly limited to the ﬁrst week after
implantation.
Patient selection
We did not change our selection process greatly for
determination of suitable candidates for this device. An
important concern is the need for pacing or ATP. However,
by using Holter recordings and analyzing them in a very
conventional way, we are able to exclude patients with
evident or symptomatic bradycardia, high degree AV block
or having pauses so that pacing function was necessary in
addition to the ICD. Further, patients with monomorphic
tachycardia who could have been candidates for ATP were
not selected. Another consideration could be that the
presence of transvenous leads might be a disadvantage
when an ablation may be indicated. Recently, it was pro-
posed that a pacemaker may be associated with the S-ICD
if necessary [15].
Limitations
This single center experience was not randomized and
shows the short term, initial experience of our group. This
implies that no real data on long-term performance of the
device and its longevity were available.
Conclusions
We had the opportunity to use a new device, which was
associated with mostly reversible complications and an
efﬁcacy that seemed reasonable for the reported follow-up.
Inappropriate shocks occurred during this short observation
time, all cases were elucidated and an efﬁcient solution (so
far) was found. It is worthwhile to perform larger trials to
gain experience with this new prophylactic device. There
was only one death in our group due to an aggressive lung
carcinoma, and there were no episodes of unexplained
syncope or hospitalizations for heart failure. This device is
also a potential alternative for patients who have had an
ICD-related complication, have a limited vascular access
or are reluctant to undergo a new implantation.
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